EP Patent

EP3089757A1 — Solid antiviral dosage forms

Assigned to AbbVie Deutschland GmbH and Co KG · Expires 2016-11-09 · 10y expired

What this patent protects

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection. In particular the application is directed to a solid dosage form comprising ABT-450 (paritaprevir), ABT-267 (ombitasvir), riton…

USPTO Abstract

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection. In particular the application is directed to a solid dosage form comprising ABT-450 (paritaprevir), ABT-267 (ombitasvir), ritonavir and ABT-333 (dasabuvir) for the treatment of infections by hepatitis C virus (HCV). As an exemplary formulation a bilayer tablet is disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3089757A1
Jurisdiction
EP
Classification
—
Expires
2016-11-09
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Deutschland GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.